Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study

dc.authorid0000-0003-2054-1691
dc.authorid0000-0002-7347-7761
dc.authorid0000-0002-6313-6031
dc.authorid0000-0001-6480-8066
dc.authorid0000-0003-2600-3536
dc.authorid0000-0002-3073-6890
dc.authorid0000-0001-6271-3776
dc.contributor.authorMente, Andrew
dc.contributor.authorDehghan, Mahshid
dc.contributor.authorRangarajan, Sumathy
dc.contributor.authorMcQueen, Matthew
dc.contributor.authorDagenais, Gilles
dc.contributor.authorWielgosz, Andreas
dc.contributor.authorLear, Scott
dc.date.accessioned2025-05-10T19:44:05Z
dc.date.issued2017
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground The relation between dietary nutrients and cardiovascular disease risk markers in many regions worldwide is unknown. In this study, we investigated the effect of dietary nutrients on blood lipids and blood pressure, two of the most important risk factors for cardiovascular disease, in low-income, middle-income, and high-income countries. Methods We studied 125 287 participants from 18 countries in North America, South America, Europe, Africa, and Asia in the Prospective Urban Rural Epidemiology (PURE) study. Habitual food intake was measured with validated food frequency questionnaires. We assessed the associations between nutrients (total fats, saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids, carbohydrates, protein, and dietary cholesterol) and cardiovascular disease risk markers using multilevel modelling. The effect of isocaloric replacement of saturated fatty acids with other fats and carbohydrates was determined overall and by levels of intakes by use of nutrient density models. We did simulation modelling in which we assumed that the effects of saturated fatty acids on cardiovascular disease events was solely related to their association through an individual risk marker, and then compared these simulated risk markerbased estimates with directly observed associations of saturated fatty acids with cardiovascular disease events. Findings Participants were enrolled into the study from Jan 1, 2003, to March 31, 2013. Intake of total fat and each type of fat was associated with higher concentrations of total cholesterol and LDL cholesterol, but also with higher HDL cholesterol and apolipoprotein A1 (ApoA1), and lower triglycerides, ratio of total cholesterol to HDL cholesterol, ratio of triglycerides to HDL cholesterol, and ratio of apolipoprotein B (ApoB) to ApoA1 (all p(trend) < 0.0001). Higher carbohydrate intake was associated with lower total cholesterol, LDL cholesterol, and ApoB, but also with lower HDL cholesterol and ApoA1, and higher triglycerides, ratio of total cholesterol to HDL cholesterol, ratio of triglycerides to HDL cholesterol, and ApoB-to-ApoA1 ratio (all p(trend) < 0.0001, apart from ApoB [p(trend) = 0.0014]). Higher intakes of total fat, saturated fatty acids, and carbohydrates were associated with higher blood pressure, whereas higher protein intake was associated with lower blood pressure. Replacement of saturated fatty acids with carbohydrates was associated with the most adverse effects on lipids, whereas replacement of saturated fatty acids with unsaturated fats improved some risk markers (LDL cholesterol and blood pressure), but seemed to worsen others (HDL cholesterol and triglycerides). The observed associations between saturated fatty acids and cardiovascular disease events were approximated by the simulated associations mediated through the effects on the ApoB-to-ApoA1 ratio, but not with other lipid markers including LDL cholesterol. Interpretation Our data are at odds with current recommendations to reduce total fat and saturated fats. Reducing saturated fatty acid intake and replacing it with carbohydrate has an adverse effect on blood lipids. Substituting saturated fatty acids with unsaturated fats might improve some risk markers, but might worsen others. Simulations suggest that ApoB-to-ApoA1 ratio probably provides the best overall indication of the effect of saturated fatty acids on cardiovascular disease risk among the markers tested. Focusing on a single lipid marker such as LDL cholesterol alone does not capture the net clinical effects of nutrients on cardiovascular risk.
dc.description.sponsorshipHeart and Stroke Foundation/Marion W Burke Chair in Cardiovascular Disease; Population Health Research Institute; Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Ontario; CIHR's Strategy for Patient Oriented Research through the Ontario SPOR Support Unit; Ontario Ministry of Health and Long-Term Care; AstraZeneca [Canada]; Sanofi-Aventis [France]; Sanofi-Aventis [Canada]; Boehringer Ingelheim [Germany]; Boehringer Ingelheim [Canada]; Servier; GlaxoSmithKline; Novartis; King Pharma; Argentina: Fundacion ECLA; Bangladesh: Independent University, Bangladesh; Mitra and Associates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de la Frontera; China: National Center for Cardiovascular Diseases; Colombia: Colciencias [6566-04-18062]; India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia [100-IRDC/ BIOTEK 16/6/21(13/2007), 07-05-IFN-BPH 010]; Malaysia: Ministry of Higher Education of Malaysia [600-RMI/LRGS/5/3(2/2011)]; Malaysia: Universiti Teknologi MARA; Malaysia: Universiti Kebangsaan Malaysia (UKM)-Hejim-Komuniti; occupied Palestinian territory: UN Relief and Works Agency for Palestine Refugees in the Near East (occupied Palestinian territory) (Canada); International Development Research Centre (Canada); Philippines: Philippine Council for Health Research Development; Poland: Polish Ministry of Science and Higher Education [290/W-PURE/2008/0]; Wroclaw Medical University; Saudi Arabia: King Saud University, Riyadh, Saudi Arabia [RG-1436-013]; South Africa: North-West University; South Africa: SANPAD (South Africa and Netherlands Programme for Alternative Development); South Africa: National Research Foundation; South Africa: Medical Research Council of South Africa; South Africa: South African Sugar Association; South Africa: Faculty of Community and Health Sciences; Sweden: Swedish Heart and Lung Foundation; Sweden: Swedish Research Council; Sweden: Swedish Council for Health, Working Life and Welfare; Sweden: King Gustaf V's and Queen Victoria's Freemason Foundation; Sweden: AFA Insurance; Sweden: Swedish Council for Working Life and Social Research; Sweden: Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning; Sweden: Vastra Gotaland Region (FOUU); Turkey: Metabolic Syndrome Society,; AstraZeneca (Turkey); Sanofi Aventis (Turkey); Sweden: Swedish state
dc.description.sponsorshipSYu is supported by the Heart and Stroke Foundation/Marion W Burke Chair in Cardiovascular Disease. The PURE study is an investigator-initiated study that is funded by the Population Health Research Institute, the Canadian Institutes of Health Research (CIHR), and the Heart and Stroke Foundation of Ontario, with support from CIHR's Strategy for Patient Oriented Research (through the Ontario SPOR Support Unit), as well as the Ontario Ministry of Health and Long-Term Care, unrestricted grants from several pharmaceutical companies (with major contributions from AstraZeneca [Canada], Sanofi-Aventis [France and Canada], Boehringer Ingelheim [Germany and Canada], Servier, and GlaxoSmithKline), and additional contributions from Novartis and King Pharma and from various national and local organisations in participating countries. These organisations include: Argentina: Fundacion ECLA; Bangladesh: Independent University, Bangladesh and Mitra and Associates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de la Frontera; China: National Center for Cardiovascular Diseases; Colombia: Colciencias (grant number 6566-04-18062); India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia (grant numbers 100-IRDC/ BIOTEK 16/6/21(13/2007) and 07-05-IFN-BPH 010), Ministry of Higher Education of Malaysia (grant number 600-RMI/LRGS/5/3(2/2011)), Universiti Teknologi MARA, and Universiti Kebangsaan Malaysia (UKM)-Hejim-Komuniti-15-2010; occupied Palestinian territory: UN Relief and Works Agency for Palestine Refugees in the Near East (occupied Palestinian territory) and International Development Research Centre (Canada); Philippines: Philippine Council for Health Research & Development; Poland: Polish Ministry of Science and Higher Education (grant number 290/W-PURE/2008/0) and Wroclaw Medical University; Saudi Arabia: Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (research group number RG-1436-013); South Africa: North-West University, SANPAD (South Africa and Netherlands Programme for Alternative Development), National Research Foundation, Medical Research Council of South Africa, South African Sugar Association, and Faculty of Community and Health Sciences; Sweden: grants from the Swedish state under the agreement concerning research and education of doctors, Swedish Heart and Lung Foundation, Swedish Research Council, Swedish Council for Health, Working Life and Welfare, King Gustaf V's and Queen Victoria's Freemason Foundation, AFA Insurance, Swedish Council for Working Life and Social Research, Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning, grant from the Swedish state under the Lakar Utbildnings Avtalet agreement, and grant from the Vastra Gotaland Region (FOUU); Turkey: Metabolic Syndrome Society, AstraZeneca (Turkey), and Sanofi Aventis (Turkey); United Arab Emirates: Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences and Dubai Health Authority, Dubai, United Arab Emirates.
dc.identifier.doi10.1016/S2213-8587(17)30283-8
dc.identifier.endpage787
dc.identifier.issn2213-8587
dc.identifier.issn2213-8595
dc.identifier.issue10
dc.identifier.pmid28864143
dc.identifier.scopus2-s2.0-85028461102
dc.identifier.scopusqualityQ1
dc.identifier.startpage774
dc.identifier.urihttps://doi.org/10.1016/S2213-8587(17)30283-8
dc.identifier.urihttps://hdl.handle.net/20.500.14730/10817
dc.identifier.volume5
dc.identifier.wosWOS:000411128600015
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofLancet Diabetes & Endocrinology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectCoronary-Heart-Disease
dc.subjectSaturated Fatty-Acids
dc.subjectLow-Income Countries
dc.subjectCardiovascular-Disease
dc.subjectRisk-Factors
dc.subjectLow-Carbohydrate
dc.subjectHdl-Cholesterol
dc.subjectSerum-Lipids
dc.subjectMiddle
dc.subjectMetaanalysis
dc.titleAssociation of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
10817.pdf
Boyut:
892.91 KB
Biçim:
Adobe Portable Document Format